Showing 831-840 of 9295 results for "".
Aesthetic Combinations: Recent Advancements
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aesthetic-combinations-recent-advancements/18882/Greg Buford, MD discusses advancements in aesthetic practice, including the most popular interventions among patients and his favorite approaches to patient management.Onexton Approved for Acne, Bellafill Debuts
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-onexton-approved-for-acne-bellafill-debuts/19019/In this edition of DermWireTV, from the editors of Practical Dermatology® magazine: Onexton is Valeant's fourth new approval in a year. We look at Suneva's renamed filler and the FDA's decision to grant breakthrough status to investigational atopic dermatitis treatment dupilumab. PLUS: This week'sDASIL and the ASDS
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dasil-and-the-asds/19054/A new partnership between DASIL and the ASDS is intended to improve and expand education for dermatologists and cosmetic surgeons. Michael H. Gold, MD explains.Merz Acquires Ulthera; Ulthera Gets Decolletage Indication, and a New Topical for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-merz-acquires-ulthera-ulthera-gets-decolletage-indication-and-a-new-topical-for-onychomycosis/19117/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine, learn the latest on the Merz/Ulthera acquisition, a new topical for toenail fungus, and FDA accepts Kythera's NDA.VShape Facial Contouring by Alma Lasers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vshape-facial-contouring-by-alma-lasers/19251/VShape is a non-invasive and pain-free treatment for facial contouring. Performed throughout the world using Alma Lasers Accent Ultra medical aesthetic technology. vShape: Bipolar RF TechnologyA Guidelines-Based Recommendations Algorithm for Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/a-guidelines-based-recommendations-algorithm-for-atopic-dermatitis/48781/Christopher Bunick, MD, FAAD, compares the four approved and recommended biologics and two approved oral JAK inhibitors for treating atopic dermatitis with oral corticosteroidsPsoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.FDA Approves New Drug for Prurigo Nodularis; Long-Term Use of Dupilumab Examined
https://practicaldermatology.com/series/dermwire-tv/fda-approves-new-drug-prurigo-nodularis-long-term-use-dupilumab-examined/26925/In this week's DermwireTV, the FDA approves Galderma's Nemluvio for adults with prurigo nodularis; a study examines the long-term use of dupilumab for atopic dermatitis; and Andrew Mastro discusses how to talk to patients about starting a Janus kinase (JAK) inhibitor for AD.Is this the Golden Age of Hair Loss Treatment?
https://practicaldermatology.com/topics/hair-nails/is-this-the-golden-age-of-hair-loss-treatment/24036/A perfect storm of many new, unrelated scientific developments also has the potential to fundamentally reshape the way we think about a disease or disease group. Dr. Peter C. Friedman believes many recent breakthroughs have profoundly changed how general dermatologists can manage patients with hairFDA Approves Axillary Hyperhidrosis Treatment; Study Examines Biologic Outcomes in Psoriasis
https://practicaldermatology.com/series/dermwire-tv/fda-approves-axillary-hyperhidrosis-treatment-study-examines-biologic-outcomes-psoriasis/26562/In this week's DermwireTV, the FDA approves a first-of-its-kind gel for axillary hyperhidrosis; a new analysis examines how smoking, BMI, and age affect biologic outcomes in psoriasis; and the CEO of Aerolase joins us to discuss the latest trends in the aesthetic laser market.